Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald Bunjes

Showing results (51-60 of 107) with videos related to

Pageof 11
Sort By:
Cancers|July 29, 2023
Optimization of Radiolabeling of a [<sup>90</sup>Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell TransplantationGordon Winter, Carmen Hamp-Goldstein, Gabriel Fischer, et al.
Blood|June 19, 2004
Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCRMatthias Ritgen, Stephan Stilgenbauer, Nils von Neuhoff, et al.
Haematologica|June 9, 2018
Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effectsDaniel Fuerst, Sandra Frank, Carlheinz Mueller, et al.
Blood|September 19, 2013
High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysisDaniel Fürst, Carlheinz Müller, Vladan Vucinic, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2008
Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative studyJunxia Yao, Clemens Bechter, Markus Wiesneth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter studyGeorg Hess, Donald Bunjes, Wolfgang Siegert, et al.
Journal of Hematology & Oncology|November 9, 2016
Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantationAvichai Shimoni, Myriam Labopin, Bipin Savani, et al.
Journal of Hematology & Oncology|April 27, 2019
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Francesco Saraceni, Myriam Labopin, Arne Brecht, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2020
FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationEduardo Rodríguez-Arbolí, Myriam Labopin, Johanna Tischer, et al.
Bone Marrow Transplantation|March 24, 2020
Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working PartyEolia Brissot, Myriam Labopin, Domenico Russo, et al.
Pageof 11

Showing results (51-60 of 107) with videos related to

Sort By:
Pageof 11
Cancers|July 29, 2023
Optimization of Radiolabeling of a [<sup>90</sup>Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell TransplantationGordon Winter, Carmen Hamp-Goldstein, Gabriel Fischer, et al.
Blood|June 19, 2004
Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCRMatthias Ritgen, Stephan Stilgenbauer, Nils von Neuhoff, et al.
Haematologica|June 9, 2018
Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effectsDaniel Fuerst, Sandra Frank, Carlheinz Mueller, et al.
Blood|September 19, 2013
High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysisDaniel Fürst, Carlheinz Müller, Vladan Vucinic, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2008
Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative studyJunxia Yao, Clemens Bechter, Markus Wiesneth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter studyGeorg Hess, Donald Bunjes, Wolfgang Siegert, et al.
Journal of Hematology & Oncology|November 9, 2016
Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantationAvichai Shimoni, Myriam Labopin, Bipin Savani, et al.
Journal of Hematology & Oncology|April 27, 2019
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Francesco Saraceni, Myriam Labopin, Arne Brecht, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2020
FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationEduardo Rodríguez-Arbolí, Myriam Labopin, Johanna Tischer, et al.
Bone Marrow Transplantation|March 24, 2020
Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working PartyEolia Brissot, Myriam Labopin, Domenico Russo, et al.
Pageof 11